

List of candidate vaccines developed against SARS-CoV

Platform	Type of candidate vaccine	Developer	Coronavirus target	Current stage of clinical evaluation/regulatory status- Coronavirus candidate	Non-coronavirus candidates	Current stage of clinical evaluation/regulatory status - other products
Non-Replicating Viral Vector	recombinant adenovirus expressing Truncated S protein (rADV-S) [106]	International Vaccine Institute (IVI)	SARS	Pre-Clinical	N/A	
Replicating Viral Vector	Recombinant measles virus Spike protein [50]	University Health Network, Canada; Center for Disease Control and Prevention (CDC)	SARS	Pre-Clinical		
Replicating Viral Vector	MV-SARS recombinant measles virus vaccine expressing SARS CoV antigen [45]	Institut Pasteur	SARS	Pre-Clinical	West nile, chik, Ebola, Lassa, Zika	Phase III
Protein Subunit	receptor binding domain (RBD) of the SARS- CoV spike (S) protein [48, 105]	Baylor College Medicine; Sabin; New York Blood Center (NYBC); University of Texas Medical Branch (UTMB); Walter Reed Army Institute of Research (WRAIR); National Institute of Allergy and Infectious Diseases (NIAID)	SARS	Pre-Clinical	N/A	
Protein Subunit	SARS recombinant spike protein plus delta inulin [49]	Vaxine Pty Ltd, Australia	SARS	Pre-Clinical	Ebola, Zika, Influenza, HepB	Phase I
Virus-like Particle	SARS VLPs S protein and influenza M1 protein [47]	Novavax	SARS	Pre-Clinical	RSV, Flu	Phase III
Inactivated Virus	rSARSCoV-E* [46]	CNB-CSIC; University of Iowa	SARS	Pre-Clinical	N/A	

DISCLAIMER:

These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.

DNA	DNA prime–protein S437–459 and M1–20 [51]	Institute of ImmunoBiology, Shanghai Medical College of Fudan University, China	SARS	Pre-Clinical		
DNA	SARS S DNA prime and HLA-A*0201 restricted peptides boost vaccine [52,53]	Sun Yat-sen University, China	SARS	Pre-Clinical		
DNA	3a DNA vaccine [54]	State Key Laboratory of Virology; Graduate University of Chinese Academy of Sciences	SARS	Pre-Clinical		
DNA	DNA vaccine VRC-SRSDNA015-00-VP ; Biojector used [71]	National Institute of Allergy and Infectious Diseases (NIAID)	SARS	Phase I	Ebola, HIV	Phase I
DNA	DNA S protein + DNA IL2 [72]	State Key Laboratory of Virology, University of Chinese Academy of Sciences	SARS	Pre-Clinical		
DNA	DNA vaccine pIRES-ISS-S1 [73]	Jilin University; Academy of Military Medical Sciences	SARS	Pre-Clinical		
DNA	M and N DNA vaccine [74]	National Hospital Organization Kinki-Chuo Chest Medical Center; Osaka Prefectural Institute of Public Health; Jichi Medical School; The University of Hong Kong; National Taiwan University College of Medicine; National Institute of Infectious Diseases; Central Institute for Experimental Animals; Pharmaceutical Frontier Laboratory	SARS	Pre-Clinical		

DISCLAIMER:

These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.

Non-Replicating Viral Vector	MVA S alone, or MVA-S prime and Ad5-S boost [107, 108]	The Rockefeller University	SARS	Pre-Clinical		
Non-Replicating Viral Vector	NC protein add-mixed with MALP-2 by intranasal route and boosting with MVA-NC by intramuscular route[62]	Helmholtz Centre for Infection Research; Technical University Munich; German Center for Environmental Health	SARS	Pre-Clinical		
Non-Replicating Viral Vector	Heterologous Adenoviral prime boost AdHu5 s AdC7-nS [63]	University of Manitoba; University of Pennsylvania School of Medicine; Southern Research Institute; Fox Chase Cancer Institute	SARS	Pre-Clinical		
Non-Replicating Viral Vector	VEEV replicon particles expressing the SARS-CoV S [28]	University of North Carolina at Chapel Hill, USA	SARS	Pre-Clinical		
Non-Replicating Viral Vector	Recombinant DI expressing S protein [66]	National Institute of Infectious Diseases, Japan	SARS	Pre-Clinical		
Protein Subunit	Recombinant truncated S-N fusion protein [60]	Beijing Institute of Genomics, China	SARS	Pre-Clinical		
Protein Subunit	Recombinant peptide N223 on liposomes [61]	Saitama Medical University; Josai University; Nippon Oil and Fat Corporation; National Institute of Infectious Diseases, Japan	SARS	Pre-Clinical		
Protein Subunit	Recombinant TM-truncated S protein [64]	Chinese Center for Disease Control and Prevention; Canadian Science Centre for Human and Animal Health	SARS	Pre-Clinical		
Protein Subunit	Trimeric Spike protein [65]	HKU-Pasteur Research Centre; The University of Hong Kong; National Institutes of Health; Centers for Disease	SARS	Pre-Clinical	N/A	

DISCLAIMER:

These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.

		Control and Prevention; CombinatorX				
Virus-like Particle	Chimeric VLP (S protein SARS plus E, M and N proteins of mouse hepatitis virus)[55]	University of Texas Medical Branch (UTMB)	SARS	Pre-Clinical	N/A	
Virus-like Particle	Recombinant trimeric S protein [56]	The John Hopkins University School of Medicine, USA	SARS	Pre-Clinical	N/A	
Inactivated Virus	purified inactivated Vero-cell SARS vaccine [57]	Institute of Microbiology and Epidemiology, National Vaccine and Serum Institute; Beijing Genomics Institute (BGI); Harbin Institute of Veterinary Medicine	SARS	Pre-Clinical	N/a	
Inactivated Virus	Formalin- and UV inactivated virus vaccine [58]	Baxter Vaccines, Austria	SARS	Pre-Clinical	N/A	
Inactivated Virus	β -propiolactone inactivated virus vaccine [59]	National Institute of Allergy and Infectious Diseases (NIAID); University of Virginia	SARS	Pre-Clinical	NA	
Live Attenuated Virus	Live attenuated vaccine Nsp16 mutant lacking 2'-OMTase [75]	University of North Carolina	SARS	Pre-Clinical	N/A	
Live Attenuated Virus	Live attenuated SARS-CoV MA- Δ ExoN [76]	University of North Carolina	SARS	Pre-Clinical	N/A	
Inactivated Virus	ISCV [81]	Sinovac Biotech Ltd (/Beijing Kexing Bio-product), Chinese Centre for Disease Control and Prevention; Chinese Academy of Medical Sciences	SARS	Phase I	N/A	
Inactivated Viral Vector	RABV-SARS [148]	Thomas Jefferson University	SARS	Pre-Clinical	Filoviruses, Hendra	Pre-Clinical
Inactivated Virus	whole virus [132]	Sanofi	SARS	Pre-Clinical	Influenza and others	Licensed Product

DISCLAIMER:

These landscape documents have been prepared by the World Health Organization (WHO) for information purposes only concerning the 2019-2020 global of the novel coronavirus. Inclusion of any particular product or entity in any of these landscape documents does not constitute, and shall not be deemed or construed as, any approval or endorsement by WHO of such product or entity (or any of its businesses or activities). While WHO takes reasonable steps to verify the accuracy of the information presented in these landscape documents, WHO does not make any (and hereby disclaims all) representations and warranties regarding the accuracy, completeness, fitness for a particular purpose (including any of the aforementioned purposes), quality, safety, efficacy, merchantability and/or non-infringement of any information provided in these landscape documents and/or of any of the products referenced therein. WHO also disclaims any and all liability or responsibility whatsoever for any death, disability, injury, suffering, loss, damage or other prejudice of any kind that may arise from or in connection with the procurement, distribution or use of any product included in any of these landscape documents.